Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study.
Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.
Immunosuppressive properties of mesenchymal stem cells: advances and applications.
Phase III study with teriflunomide versus placebo in patients with first clinical symptom of multiple sclerosis (TOPIC)
Treatment of progressive multiple sclerosis: what works, what does not, and what is needed.
Receptos to Deliver Scientific Presentations Regarding RPC1063 at the 2014 American Academy of Neurology (AAN) Annual Meeting
Biogen Idec submits application to FDA for approval of PLEGRIDY™ (peginterferon beta-1a) in multiple sclerosis
Rituximab product approval information - Licensing action
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
Multiple Sclerosis and Pregnancy: Current Considerations.
Interferon β-1b directly modulates human neural stem/progenitor cell fate.
Effect of Glatiramer Acetate on Peripheral Blood Brain-Derived Neurotrophic Factor and Phosphorylated TrkB Levels in Relapsing-Remitting Multiple Sclerosis.
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.
Inflammatory cortical demyelination in early multiple sclerosis.
The scales and tales of myelination: using zebrafish and mouse to study myelinating glia.
Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration.
Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.
Launch of a phase 3 clinical trial in the treatment of Alzheimer’s disease with masitinib
Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.

Pages